Cadrenal Therapeutics, Inc. financial data

Symbol
CVKD on Nasdaq
Industry
Pharmaceutical Preparations
Location
822 A1 A North, Suite 300, Ponte Vedra, FL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 581 % -13.6%
Debt-to-equity 20.7 % -71.9%
Return On Equity -143 % +69.5%
Return On Assets -118 % +56.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.66M shares -87.3%
Common Stock, Shares, Outstanding 1.23M shares -90.5%
Entity Public Float 6.4M USD -51.8%
Common Stock, Value, Issued 1.23K USD -90.5%
Weighted Average Number of Shares Outstanding, Basic 1.1M shares +7.56%
Weighted Average Number of Shares Outstanding, Diluted 1.1M shares +7.56%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.03M USD -54.9%
General and Administrative Expense 4.92M USD +36.3%
Operating Income (Loss) -7.95M USD -6.73%
Nonoperating Income (Expense) 338K USD -50.9%
Net Income (Loss) Attributable to Parent -7.61M USD +37.8%
Earnings Per Share, Basic -1.47 USD/shares +33.5%
Earnings Per Share, Diluted -1.47 USD/shares +37.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.36M USD -52.1%
Assets, Current 4.67M USD -49.6%
Property, Plant and Equipment, Net 814 USD -71.8%
Operating Lease, Right-of-Use Asset 2.2K USD -91.8%
Other Assets, Noncurrent 3.79K USD 0%
Assets 4.68M USD -49.7%
Accounts Payable, Current 497K USD +251%
Employee-related Liabilities, Current 613K USD
Accrued Liabilities, Current 768K USD +93.5%
Liabilities, Current 1.27M USD +125%
Operating Lease, Liability, Noncurrent 2.23K USD
Liabilities 1.27M USD +124%
Retained Earnings (Accumulated Deficit) -21.5M USD -54.6%
Stockholders' Equity Attributable to Parent 3.41M USD -61%
Liabilities and Equity 4.68M USD -49.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.84M USD -30%
Net Cash Provided by (Used in) Financing Activities 5.41M USD +969%
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 1.23M shares -90.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.36M USD -52.1%
Deferred Tax Assets, Valuation Allowance 2.18M USD +355%
Deferred Tax Assets, Gross 2.19M USD +311%
Operating Lease, Liability 2.23K USD -91.8%
Depreciation 2.07K USD -31.8%
Lessee, Operating Lease, Liability, to be Paid 2.23K USD -92.3%
Operating Lease, Liability, Current 2.23K USD -91.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 22.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 22.3K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 132 USD -94.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 22.3K USD
Deferred Tax Assets, Operating Loss Carryforwards 1.1M USD +269%
Preferred Stock, Shares Authorized 7.5M shares
Additional Paid in Capital 24.9M USD +10.1%
Preferred Stock, Shares Outstanding 7.5M shares
Share-based Payment Arrangement, Expense 759K USD +96%
Interest Expense 41.6K USD +69.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares